Alan B. Lancz & Associates, Inc. Amgen Inc Transaction History

Alan B. Lancz & Associates, Inc.

$108 Million
Q3 2024

A detailed history of Alan B. Lancz & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 11,980 shares of AMGN stock, worth $3.83 Million. This represents 3.58% of its overall portfolio holdings.

Number of Shares

11,980

Previous 12,030 0.42%

Holding current value

$3.83 Million

Previous $3.76 Million 2.71%

% of portfolio

3.58%

Previous 3.75%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$309.38 - $337.38 $15,469 - $16,869	-50 Reduced 0.42%	11,980 $3.86 Million
Q2 2024 Jul 24, 2024	BUY	$262.75 - $319.31 $93,276 - $113,355	355 Added 3.04%	12,030 $3.76 Million
Q4 2023 Feb 06, 2024	SELL	$255.7 - $288.46 $25,570 - $28,845	-100 Reduced 0.85%	11,675 $3.36 Million
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $21,865 - $27,145	-100 Reduced 0.84%	11,775 $3.16 Million
Q2 2023 Aug 09, 2023	BUY	$214.27 - $253.37 $107,135 - $126,685	500 Added 4.4%	11,875 $2.64 Million
Q1 2023 May 05, 2023	BUY	$225.79 - $275.2 $56,447 - $68,800	250 Added 2.25%	11,375 $2.75 Million
Q2 2022 Aug 11, 2022	SELL	$230.71 - $256.74 $109,587 - $121,951	-475 Reduced 4.09%	11,125 $2.75 Million
Q4 2021 Apr 13, 2022	SELL	$198.88 - $227.6 $3.28 Million - $3.76 Million	-16,500 Reduced 58.72%	11,600 $2.61 Million
Q4 2021 Feb 09, 2022	BUY	$198.88 - $227.6 $5.59 Million - $6.4 Million	28,100 New	28,100 $6.32 Million

Others Institutions Holding AMGN

# of Institutions

3,090

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.13M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alan B. Lancz & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Alan B. Lancz & Associates, Inc. with notifications on news.

Account

Alan B. Lancz & Associates, Inc. Amgen Inc Transaction History